Blood Group Genotyping for Sickle Cell and Thalassaemia
key details
| Status | complete |
|---|---|
| Procedure | direct |
| OCID | ocds-h6vhtk-05f01d |
Award
| Supplier | Value | Date | Status |
|---|---|---|---|
| NHSBT | £140,671 | 14 May 2025 | active |
description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.
Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026.
notice history
4 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 5 Dec 2025 | Transparency notice (UK5) | Procurement Act 2023 | 080318-2025 |
| 5 Dec 2025 | Contract award (UK6) | Procurement Act 2023 | 080350-2025 |
| 10 Jun 2026 | Contract details (UK7) | Procurement Act 2023 | 054590-2026 |
| 10 Jun 2026 | Contract termination (UK11) | Procurement Act 2023 | 054644-2026 |
more from NHS England
- Membership of London Higher Academic Organisation · £16,550 · 11 Sept 2026
- Babies, Children and Young People Modern Service Framework · · · 10 Sept 2026
- Primary Care Virtual Licences · £19,940 · 10 Sept 2026
- Access to medicine and the professions 2026/27 · £115,000 · 10 Sept 2026
- SANS Training 26/27 · £400,000 · 9 Sept 2026
- Discovery into the Professionalisation of the NHS DDaT Workforce · £50,000 · 8 Sept 2026
- NHS Graduate Management Training Scheme(GMTS) Engineering and Estates Management - NHSE · £825,000 · 8 Sept 2026
- Elizabeth Garrett Anderson Programme – Primary Care Manchester University · £662,000 · 7 Sept 2026
all contracts from this buyer →
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.